Topical cosmetic peptide
SNAP-8
SNAP-8 is a cosmetic peptide that the COSMILE Europe database lists with humectant and skin-conditioning functions; the app lists a half-life of 4 hours.1
SNAP-8 after one dose: 50% at ~4 h, 25% at 8 h, 12.5% at 12 h.
Drawn from the half-life in the app's model, ~4 h. The model's figures
- Compound
- SNAP-8
- Symbol
- SN8
- Family
- Cosmetic and copper peptides
- Parts
- 12
- References
- 4
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
SNAP-8 is a trade name for the cosmetic ingredient acetyl octapeptide-3; Shin and colleagues (Annals of Dermatology, 2024) write both names together as "acetyl octapeptide-3 (SNAP-8TM)".2 The COSMILE Europe database, credited to Cosmetics Europe, lists acetyl octapeptide-3 with the functions humectant ("Holds and retains moisture in cosmetic products") and skin conditioning ("Maintains the skin in good condition").1 The app grades the evidence for SNAP-8 as limited, and the two clinical studies identified tested acetyl octapeptide-3 only as one ingredient among several in microneedle patches.2,3 No controlled trial of acetyl octapeptide-3 as a single ingredient in a topical formulation was identified in PubMed or ClinicalTrials.gov.
How it works
Sources in this part
Shin and colleagues describe acetyl octapeptide-3 as "a botulinum toxin analog which acts by blocking neurotransmitters and relaxing muscles to improve wrinkles" and give its sequence as Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2, eight amino acids.2 They add that it "reportedly influences muscle contraction resulting in a more relaxed and line-free face"; this is a description in the introduction, and the study measured skin roughness, water loss, elasticity and eye lifting, not muscle activity.2 The app's notes describe it as an elongated peptide extending Argireline's mechanism (SNAP-25 and SNARE inhibition). For Argireline (acetyl hexapeptide-8), a different and shorter peptide, a 2025 review by Zdrada-Nowak and colleagues in the International Journal of Molecular Sciences states that it "inhibits neurotransmitter release by disrupting the formation and stabilization of the SNARE complex"; that statement is about the hexapeptide, not SNAP-8.4
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~4 h
- Bioavailability
- 95%
- Typical dose
- 5–10 %
- Route
- Topical
- Time to peak
- ~0.5 h
No pharmacokinetic study of acetyl octapeptide-3 in people was identified in PubMed or ClinicalTrials.gov, so the table gives the app's figures beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~4 h | No measurement identified |
| Bioavailability | 95% | No measurement identified; the app's own notes call systemic absorption negligible |
| Time to peak | ~0.5 h | No measurement identified |
The app's notes state that it is a topical ingredient with negligible systemic absorption, that systemic tracking is not applicable and that the modeled curve does not reflect how it works; none of the retrieved studies report blood or tissue levels.
Human studies
Both studies below used patches that deliver peptides through microneedles, so their results belong to the whole patch and not to acetyl octapeptide-3 alone.2,3
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Shin and colleagues, Annals of Dermatology 20242 | Comparative study of a three-ingredient patch containing acetyl octapeptide-3 against a hyaluronic acid-only placebo patch, one on each eye; acknowledgment: supported by Raphas Co., Ltd.2 | 24 enrolled and 21 completed; subjects with eye wrinkles aged 30–652 | Patch with 0.03% SNAP-8; nightly for 14 days, then every 3 days to day 282 | All roughness parameters R1 to R5 differed from placebo on day 28 (p under 0.05); skin elasticity was similar between the groups; no adverse events observed2 |
| Avcil and colleagues, Journal of Cosmetic Dermatology 20203 | Monocentric clinical trial of hyaluronic acid microneedle patches containing acetyl octapeptide-3 with other ingredients; no comparator is stated in the PubMed record; grant listed to Imperial Bioscience3 | Healthy subjects with aged skin; number not given in the PubMed record3 | 12 weeks; patches at the outer corner of the eyes and the volar forearm; content of acetyl octapeptide-3 not given3 | Fine lines and wrinkles showed a 25.8% decrease, hydration 15.4% improvement, and dermal skin density and thickness increased 14.2% and 12.9%, with no comparator, time point or p-value in the record; none of the subjects reported any primary or cumulative skin reactions3 |
Sources in this part
Deeper analysis: Shin and colleagues, microneedle patch (2024)
Shin, Han, Yoon and Jeong list Raphas Co., Ltd., Seoul, as their affiliation, and Park lists the Department of Biotechnology, Graduate School, The Catholic University of Korea.2 The active patch held acetyl octapeptide-3 together with L-ascorbic acid 2-glucoside and sodium cyclic lysophosphatidic acid, while the placebo patch was hyaluronic acid alone, so the comparison is of the three-ingredient patch against hyaluronic acid.2 Each of the 24 subjects had the active patch on one eye and the placebo patch on the other; 3 dropped out, and 21 completed.2 Skin roughness (R1) and average roughness (R3) fell significantly on days 14 and 28 with the active patch, and the other roughness measures (R2, R4, R5) on day 28 only.2 Skin elasticity was similar between the two groups, and the within-group Rv valley-depth parameter was similar for the active and placebo patches at all time points, although Rv differed between the groups on day 28; the Fig. 6 caption states that wrinkle improvement "was confirmed in both groups" and continues that the active group "showed better wrinkle improvement compared to the placebo group".2 Among the secondary measures, trans-epidermal water loss decreased in the active group with no change in the placebo group, and the eye-lifting measure differed from placebo on day 14.2 The authors state that the improvement after a single use "appears to be due to the short-term effect of SNAP-8’s muscles relaxing mechanism"; the design did not separate that ingredient from the other two.2 For safety, the authors report that erythema, edema and scaling "were not observed at all visits", and write that "the skin safety concern generally needs to be confirmed through a larger clinical study".2 The acknowledgment reads "This research was supported by Raphas Co., Ltd.", the funding statement reads "FUNDING SOURCE: None." and the conflict statement reads "The authors have nothing to disclose."2
Deeper analysis: Avcil and colleagues, microneedle patches (2020)
Avcil and colleagues report authors at Imperial Bioscience Ltd. (Brighton, UK), Dermatest GmbH (Münster, Germany) and Raphas Co. Ltd. (Seoul, Korea), with the grant listed to Imperial Bioscience.3 The study lists acetyl octapeptide-3 among five ingredients and reports that wrinkles decreased 25.8% and hydration improved 15.4%, without giving a comparator, participant number or p-value in the PubMed record.3 The authors conclude that "all ingredients might possibly be acted synergistically", so the results cannot be assigned to acetyl octapeptide-3.3
Doses reported in studies and on labels
No product label for acetyl octapeptide-3 was identified; the table lists what the two studies and the app report.
| Source | Preparation | Acetyl octapeptide-3 content | Route and schedule |
|---|---|---|---|
| Shin and colleagues 20242 | Hyaluronic acid microneedle patch, 350 μm long, with two other actives | 0.03% SNAP-8 in the patch composition | Applied to the eye area nightly for 14 days, then every 3 days to day 28 |
| Avcil and colleagues 20203 | Hyaluronic acid microneedle patch with four other ingredients | Not given in the PubMed record | Eye corner and volar forearm; 12 weeks |
| The app | Topical serum, per the app's notes | 5–10 % (roughly 5-10% serum concentration) | Topical |
Sources in this part
The 0.03% in the patch is far below the app's 5–10 %, but the two figures describe different preparations (a dissolving patch against a serum), so they are not a like-for-like comparison.
Side effects reported
Sources in this part
In Shin and colleagues' 28-day study, erythema, edema and scaling were not observed at any visit, and no adverse effects were observed with repeated use in the same skin area.2 Avcil and colleagues report that "none of the subjects reported any primary or cumulative skin reactions" over 12 weeks.3 Both reports concern combination patches, and Shin and colleagues write that safety "needs to be confirmed through a larger clinical study".2
Regulatory and anti-doping status
Sources in this part
The COSMILE Europe entry for acetyl octapeptide-3 is an ingredient-database record, not a regulator's assessment; it states that "Cosmetics Ingredients are subject to regulation" and that "different regulations may apply to cosmetic ingredients outside the EU".1 The European Commission's CosIng record for the ingredient could not be read in this review, and no regulator's safety opinion or anti-doping listing for acetyl octapeptide-3 was retrieved.
What is not known
- No pharmacokinetic measurement of acetyl octapeptide-3 in people, including skin penetration, was identified in PubMed or ClinicalTrials.gov, so the app's half-life, bioavailability and time-to-peak figures have no measured figure from a study beside them.
- Whether acetyl octapeptide-3 alone changes wrinkles in people is not answered by the two patch studies, which tested it with other ingredients.
- The mechanism of SNAP-25 and SNARE inhibition in the app's notes is not tested in the studies retrieved; Shin and colleagues describe it as "reportedly" influencing muscle contraction.
Frequently asked questions
What is SNAP-8?
What is the half-life of SNAP-8?
The app lists a half-life of about 4 hours, and no measured half-life for acetyl octapeptide-3 in people was identified in PubMed or ClinicalTrials.gov.
How many amino acids does SNAP-8 have?
SNAP-8 has eight amino acids, with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2 as given by Shin and colleagues.2
Has SNAP-8 been studied in people?
Is SNAP-8 the same as Argireline?
What functions does a cosmetic ingredient database list for SNAP-8?
The COSMILE Europe database lists humectant and skin conditioning for acetyl octapeptide-3.1
What side effects have been reported with SNAP-8?
In the 28-day study of Shin and colleagues no adverse effects were observed, and the Avcil record states that none of the subjects reported any primary or cumulative skin reactions over 12 weeks; both tested combination patches, and Shin and colleagues write that safety "needs to be confirmed through a larger clinical study".2,3
Does SNAP-8 enter the bloodstream?
No measurement of SNAP-8 in blood or tissue was identified, and the app's notes call systemic absorption negligible while listing a bioavailability of 95%.
Guides, tools and comparisons
References
- Cosmetics Europe. Acetyl octapeptide-3. COSMILE Europe cosmetic ingredient database, accessed 16 November 2026. COSMILE Europe entry
- Shin JY, et al. Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities. Ann Dermatol 2024. PMID 39082657
- Avcil M, et al. Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study. J Cosmet Dermatol 2020. PMID 31134751
- Zdrada-Nowak J, et al. Acetyl Hexapeptide-8 in Cosmeceuticals: A Review of Skin Permeability and Efficacy. Int J Mol Sci 2025. PMID 40565185